Stocklytics Platform
Asset logo for symbol INCY
Asset logo for symbol INCY



AI Deep-Learning Forecast (INCY)

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Incyte (INCY) Stocklytics Forecast

Incyte Corp (NASDAQ: INCY) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. With a strong track record of successful drug development, Incyte Corp has positioned itself as a leading player in the biotech industry. The company's stock price has been a subject of interest for investors, prompting many to seek out price predictions and forecasts for INCY.

Looking ahead, the future prospects for Incyte Corp appear promising. The company has a robust pipeline of potential blockbuster drugs in various stages of development. One of the most highly anticipated drugs is Jakafi, which is used to treat certain types of hematologic malignancies. Analysts believe that Jakafi has the potential to generate significant revenue for Incyte Corp and drive the company's growth in the coming years.

add Incyte to watchlist

Keep an eye on Incyte

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

What is the analyst price prediction for Incyte (INCY) stock?

Analysts have set a target price of $74.62 for Incyte (INCY), based on forecasts from 26 analysts. The predicted price range extends from a high of $98 to a low of $52. This represents a potential increase of up to 48.94% and a decrease of -20.97% from the current price of $65.8. These forecasts are as of 2023 Aug 02.

What are the analyst ratings for Incyte (INCY) stock?

Currently, there are no analyst ratings available for Incyte (INCY), possibly due to insufficient coverage or recent updates.

What is the AI price prediction for Incyte (INCY) stock?

At present, there is no AI or machine-learning-based price prediction available for Incyte (INCY) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level